Notes on skin and delivery
On the skin, Topical Peptides meet a stubborn barrier.
A cream can feel lovely without telling you where its peptides went. We follow research peptides, led by GHK-Cu, from the label to what was actually tested.
On the skin isn’t the same as through the skin
Topical tells you where something is applied: on the surface. Whether its peptide gets past skin’s outer barrier is another question. A serum can spread beautifully while leaving that unanswered.
Skin has an outer barrier, and getting a peptide past it can be tricky. A review of topical GHK research puts that problem front and centre. The cream or liquid carrying the peptide is part of the story.
Then there’s another question: did it help? Finding an ingredient in skin and seeing fewer wrinkles are different results. Our comparison of routes separates those steps without the chemistry homework.
GHK-Cu gives us something concrete to look at
Three amino acids make up GHK; add copper, and you have GHK-Cu. On skincare labels, it’s often called Copper Tripeptide-1. The name tells you an ingredient, rather than everything about the finished cream.
There are encouraging findings. A review of skin research reports better-looking skin and fewer fine lines in small face-cream studies. Its references for those findings are a conference presentation, a report from a university and a chapter in a book. We’re seeing the trials through summaries, which limits what we can check.
A lab experiment on pieces of human skin found copper passing through. It measured copper, not the whole GHK-Cu molecule. Our GHK-Cu page explains why that small detail changes the claim.
An injection is a separate conversation
A face cream’s history can’t tell us whether an injection is safe. The route changes, and so do the questions.
For injectable GHK-Cu, FDA flags possible immune reactions linked to clumping and impurities. Human safety information is limited. On FDA’s page current as of April 22, 2026, the injectable entry is in the withdrawn-nomination table. That means a request was withdrawn, not that FDA cleared it.
Follow the preparation, wherever it goes
Semaglutide has approved tablets and injections, each with evidence for its own form. Thymosin alpha-1 nasal spray raises a different question: what can injection research really tell us about a spray?
That’s the thread running through these pages. Keep the ingredient, what carries it and how it’s used together. A familiar name is a useful beginning; the research behind the preparation is where we look next.